To sign up for our free research reports and newsletters, visit http://beaconequityresearch.com/. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Campbell Resources Inc. (OTCBB: CBLRF) Up 13.64% on Monday
Detailed quote: http://beaconequityresearch.com/CBLRF
December 03, 2007 - MSV Resources obtains its certificate of execution
Campbell Resources Inc. (TSX: CCH, OTC Bulletin Board: CBLRF) ("Campbell") is pleased to announce that Raymond Chabot Inc., the Court appointed Monitor of MSV Resources Inc. ("MSV") has certified that MSV has now fulfilled all of its obligations with respect to its Plan of arrangement made pursuant to the Companies Creditors Arrangement Act (the "CCAA") and that a Certificate of Execution has been filed as at November 27, 2007. Both Campbell and GoNova Explorations Inc. exited CCAA earlier this year.
Furthermore, The Quebec Superior Court has granted Meston Resources Inc.'s ("Meston") request for an additional extension to May 31, 2008 of the initial order granted June 30, 2005 under the CCAA to allow Meston.to fulfil its obligations under its Plan of arrangement.
Avitar Inc. (OTCBB: AVTI) Up 12.50% on Monday
Detailed quote: http://beaconequityresearch.com/AVTI
December 03, 2007 - Avitar Aims to Increase Its Share of $1.5B Diagnostic Market
Avitar Inc. ("AVTI") (OTCBB:AVTI), manufacturers of nationally branded oral fluid testing diagnostic devices and customized polyurethane applications used in wound dressings, announced today that, because of a recent GAO study of the Department of Transportation urine-based testing procedures and their high rate of failures, the patented Avitar ORALscreen(R) technology will quickly gain favor. Drug abuse remains a major problem in the transportation sector, as well as construction, manufacturing, hospitality, and retail, due to the limitations associated with urine-based drug testing.
Peter Phildius, Avitar's Chairman and CEO, discussed the GAO study. "We believe that the door is now open wide for us to capture a large segment of the estimated $1.5B drug testing market. We are already selling to several cross-sector industry leaders, (Best Buy, Del Monte, Hilton, Sheraton and ADM), as well as small- to mid-sized companies that are receiving multiple benefits, such as lower employee turnover, higher quality workforce, and reductions of up to 50% in their accident rates. There is no competitive product to our ORALscreen(R) instant on-site testing device which detects prescription pain relievers such as Oxycontin(R) and Percoset(R), as well as other commonly abused substances in 15 minutes or less."
Being relatively unknown for the past six years, the Company looks to 2008 as a banner year for rapid expansion into all segments of the drug testing market. The Company has hired a PR firm to begin "telling our story", elevating investor awareness and shareholder value.
Interactive Motorsports and Entertainment Corporation (OTCBB: IMTS) Up 12.50% on Monday
Detailed quote: http://beaconequityresearch.com/IMTS
December 03, 2007 - Interactive Motorsports' Simulators Debut as Part of a Three-Week Trial on Carnival Triumph Cruise Ship
Interactive Motorsports and Entertainment Corporation (OTCBB: IMTS), a leading producer of race car simulators, today issued photos of two of their proprietary race car simulators being lifted by crane onto the Carnival Cruise Lines' cruise ship Carnival Triumph in the Port of Miami.
The two NASCAR simulators will be a featured attraction on the Lido Deck of the Carnival Triumph cruise ship during a three week-long cruise test aboard the vessel November 24 to December 15. The December 1 departure includes the line's popular Rusty Wallace Cruise series.
"In addition to offering a unique experience for the Carnival cruise guests, we plan to display a top twelve leader board during the week, and create a competition to crown a cruise racing champion each week," said Interactive Chairman and CEO William R. Donaldson. "Cruise ships are one of our many targets for installations going forward, and we look forward learning from the current Carnival cruise test."
Ceragenix Pharmaceuticals, Inc. (OTCB: CGXP) Up 12.24% on Monday
Detailed quote: http://beaconequityresearch.com/CGXP
December 03, 2007 - Ceragenix Announces Promising Antimicrobial Coating Data
Ceragenix Pharmaceuticals, Inc. (OTCB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology today announced that recent in vitro testing has shown that its Cerashield(TM) antimicrobial coating applied to endotracheal tube segments was able to completely prevent bacterial adhesion and biofilm formation in a 14 day continuous challenge with 10E6 of Pseudomonas aeruginosa.
In this test procedure, both uncoated and Cerashield(TM) coated tube segments were exposed to daily challenges of 1 million colony forming units per ml of Pseudomonas aeruginosa in nutrient media broth. The broth was changed on a daily basis and fresh inocula of bacteria were added daily for 14 consecutive days. On days 7 and 14, uncoated and coated tube segments were removed and evaluated for 1) bacterial adhesion; and 2) biofilm growth. The uncoated tube segments showed substantial bacterial adherence (over 500,000 Colony Forming Units) and extensive biofilm coverage while the Cerashield(TM) treated segments showed no bacterial adherence and no biofilm formation. All assays were run in triplicate. The testing was conducted at Brigham Young University under the supervision of Dr. Paul B. Savage, inventor of the Cerashield(TM) technology.
According to the US Centers for Disease Control and Prevention, there are over 250,000 cases annually of ventilator associated pneumonia and over 60,000 deaths. Ventilator associated pneumonia has been shown to be linked to bacterial contamination and biofilm growth on endotracheal tubes which are commonly used in the ICU to help critically ill patients breathe. It is thought that bacterial growth on the endotracheal tube may serve as a reservoir for bacterial infections. Among the various bacteria that are known to grow on endotracheal tubes, pseudomonas aeruginosa is one of the most dangerous and difficult to eradicate. Third-party payor costs for treatment of ventilator associated pneumonia are estimated to be in excess of 8 billion dollars annually.
Professor Sean P. Gorman, Head of School of the School of Pharmacy at Queen's University Belfast, and a member of the Company's Scientific Advisory Board stated, "Protection of the ventilated patient from life-threatening infection is a priority. These most recent excellent results from Ceragenix show significant promise in, importantly, sustained protection of the endotracheal tube surface from infection by a key pathogen implicated in nosocomial pneumonia."
Steven Porter, Chairman and CEO of Ceragenix said, "We are very pleased with the outcome of these early tests that have shown the promising capability of our antimicrobial coating for which we won the Frost & Sullivan award this past year. Given the emerging crisis in mutating bacteria and the resultant hospital derived infections, half of which come from implanted medical devices, a coating that can prevent bacterial colonization of such devices is both timely and critically important."
China Organic Agriculture, Inc. (OTCBB: CNOA) Up 9.16% on Monday
Detailed quote: http://beaconequityresearch.com/CNOA
December 03, 2007 - China Organic Agriculture Forecasts Record Revenue and Earnings for 2007
China Organic Agriculture, Inc. (OTCBB:CNOA), today increased revenue and earnings forecasts for 2007. The upwardly revised guidance projects revenues to increase to approximately $45 million for calendar year 2007, a 500% increase over the $9 million for the comparable period the previous year. The Company has also raised projected earnings to more than $14 million, an estimated $0.29 in earnings per share, for calendar year 2007, an increase of approximately 408% over the $3.43 million for the comparable period the previous year.
This new guidance reflects benefits expected as a result of corporate initiatives to increase productivity as well as a series of recently signed strategic cooperative agreements with major retail system distribution partners throughout China. The updated financial forecast follows CNOA's recently announced production and distribution partnerships with Nanjing Suguo Supermarket, Beijing Hualian Supermarket, Changchun Huaxing Ltd, Changchun Qinghai Oil and Grain Ltd, Songyuan Oil and Grain Ltd. Those new contracts are anticipated to generate a total of $21 million in revenues for the period.
"These strategic sales agreements help China Organic purchase and process green and organic rice with higher margins and also enables us to increase our production significantly in a short amount of time," said Huizhi Xiao, Chairman of China Organic Agriculture "In addition, these new contracts better ensure the successful sales of our newly produced rice, helping us achieve our sales goals and generating increased returns and value for our shareholders. We are very pleased with our projected revenues for this calendar year and expect another strong year of sustainable growth in the years to come."
The Company is firmly committed to expanding operations and increasing earnings and has already set in motion several initiatives to expand capacity and extend its reach into other fast-growing economies in Asia. Due to partnerships such as with Hualian and with Suguo, China Organic has posted approximately 100% growth for the trailing four years.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has not been compensated by any of the companies covered in this release. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
